These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36467033)

  • 1. Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China.
    Han G; Hu S; Zhang X; Qiu Z; Huang Z
    Front Pharmacol; 2022; 13():1011624. PubMed ID: 36467033
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients.
    Wei R; Wang W; Huang X; Qiao J; Huang J; Xing C; Pan Q; Guo L
    Diabetol Metab Syndr; 2023 Aug; 15(1):173. PubMed ID: 37598203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
    King AB; Philis-Tsimikas A; Kilpatrick ES; Langbakke IH; Begtrup K; Vilsbøll T
    Diabetes Technol Ther; 2017 Apr; 19(4):255-264. PubMed ID: 28282219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.
    McCrimmon RJ; Falla E; Sha JZ; Alsaleh AJO; Lew E; Hudson R; Baxter M; Palmer K
    Diabetes Ther; 2021 Dec; 12(12):3217-3230. PubMed ID: 34714523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
    Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
    Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
    Norwood P; Chen R; Jaeckel E; Lingvay I; Jarlov H; Lehmann L; Heller S
    Diabetes Obes Metab; 2017 Nov; 19(11):1562-1569. PubMed ID: 28417535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.
    Pöhlmann J; Russel-Szymczyk M; Holík P; Rychna K; Hunt B
    Diabetes Ther; 2019 Apr; 10(2):493-508. PubMed ID: 30706364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.
    Psota M; Psenkova MB; Racekova N; Ramirez de Arellano A; Vandebrouck T; Hunt B
    Clinicoecon Outcomes Res; 2017; 9():749-762. PubMed ID: 29276398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.
    Hu S; Wang S; Qi C; Gu S; Shi C; Mao L; Fan G
    Front Pharmacol; 2022; 13():831364. PubMed ID: 35250578
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes.
    Torre E; Bruno GM; Di Matteo S; Martinotti C; Oselin M; Valentino MC; Parodi A; Bottaro LC; Colombo GL
    Clinicoecon Outcomes Res; 2018; 10():413-421. PubMed ID: 30100746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.
    McCrimmon RJ; Lamotte M; Ramos M; Alsaleh AJO; Souhami E; Lew E
    Diabetes Ther; 2021 Dec; 12(12):3231-3241. PubMed ID: 34714524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China.
    Su W; Li C; Zhang L; Lin Z; Tan J; Xuan J
    Diabetes Ther; 2019 Oct; 10(5):1969-1984. PubMed ID: 31482483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
    Ericsson Å; Glah D; Lorenzi M; Jansen JP; Fridhammar A
    PLoS One; 2018; 13(2):e0191953. PubMed ID: 29408938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic.
    Kvapil M; Prázný M; Holik P; Rychna K; Hunt B
    Diabetes Ther; 2017 Dec; 8(6):1331-1347. PubMed ID: 29063511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
    Holst JJ; Buse JB; Rodbard HW; Linjawi S; Woo VC; Boesgaard TW; Kvist K; Gough SC
    J Diabetes Sci Technol; 2015 Oct; 10(2):389-97. PubMed ID: 26443290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.
    Freemantle N; Mamdani M; Vilsbøll T; Kongsø JH; Kvist K; Bain SC
    Diabetes Ther; 2015 Dec; 6(4):573-591. PubMed ID: 26582052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico.
    Garnica-Cuellar JC; Morales-Villegas E; López-Forero CA; Monroy-Cruz B; Pariti B; Deshwal S; Sekharan M; Osorio-Hernández M; García-Appendini IC
    Pharmacoecon Open; 2023 Sep; 7(5):841-849. PubMed ID: 37452964
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.